Dacogen(TM) Data Presented at the 45th Annual Meeting of the American Society of Hematology (ASH) 18 abstracts and presentations describe clinical and preclinical data DUBLIN, Calif., Dec. 5 /PRNewswire-FirstCall/ -- SuperGen, Inc. announced today that a variety of preclinical and clinical data from studies involving the investigational anticancer compound Dacogen(TM) (decitabine for injection) will be presented at the 45th Annual Meeting of the American Society of Hematology (ASH) in San Diego. 18 abstracts and presentations of both clinical and preclinical studies involving Dacogen were published in the November 16, 2003 issue of Blood (volume 102, issue 11), all but one of which will be presented during the meeting. These abstract and presentations include: Clinical Data: -- #58 - Effective Combination Treatment with Imatinib (Gleevec(TM)) Requires Residual Bcr-Abl-Induction in Imatinib-resistant Cell Lines: Oral Session -- #1541 - LDH is an Important Risk Factor to Predict Survival in Patients with MDS Treated with 5-aza-2'-deoxycytidine (decitabine). Poster Session -- #1551 - Karyotypic Stability or Chromosomal Evolution during Treatment with a DNA Demeythylating Agent? A serial Study of Patients with the Myelodysplastic Syndrome. Poster session -- #3383 - Phase I Study of a Imatinib and Tripifarnib (Zarnestra(TM), R115777) in Patients with Chronic Myeloid Leukemia in Chronic Phase Refractory to Imatinib. Poster Session -- #3385 - Phase II Study of 5-aza-2'-deoxycytidine (decitabine) in Patients with Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (Gleevec(TM)). Poster Session Preclinical Data: -- #947 - Globin Promoter Methyl CpG Density is a key Factor in ?-Globin Gene Silencing. Poster Session -- #765 - AML1/ETO Associates with DNA Methyltransferase 1 (DNMT1) in Inducing Transcriptional Repression of the AML1-Target Gene Interleukin-3 (IL-3): Oral Session -- #775 - Activation of the Silenced MLL (ALL-1) Wild-Type Allele in Acute Myeloid Leukemia (AML) with the MLL Partial Tandem Duplication Results in Enhancement of Cell Death: Oral Session -- #1412 - Combined Effect of Phenylbutyrate and 5-aza-2'-deoxycytidine (decitabine) in t(8;21) AML Leukemia Cells in Vitro and In Vivo: Poster Session -- #2295 - Preclinical Studies of the Combination of the Hypomethylating Agent 5-aza-2'-Deoxycytidine (Decitabine) and the Histone Deacetylase Inhibitor (HDI) Valproic Acid (VPA) in Leukemic Cell Systems. Poster Session -- #2315 - Characterization and DNA Methyltransferase Inhibitor Treatment of Primary Murine T/NK Acute Lymphoblastic Leukemia (ALL). Poster Session -- #2403 - SAHA, a Histone Deacetylase Inhibitor, Induces Apoptosis in Cutaneous T Cell Lymphoma Cells and is Synergistic with 5-Aza-2'- Deoxtcytidine (decitabine). Poster Session -- #2404 - Decitabine Up-Regulates the Expression of the Cancer-Associate Prame Antigen in Early Chronic Phase CML Cells. Poster Session -- #2514 - Direct and Indirect Effects of Decitabine on Gene Expression in Burkitt's Lymphoma (EBV+) and Human Myeloma (EBV-) Cell Lines. Poster Session -- #2574 - Ex-Vivo Culture Rescues Radioprotective and Long-Term Repopulating Stem and Progenitor Cells Following Harvest from Lethally Irradiated Animals. Poster Session -- #3163 - Role of Promoter Methylation in Regulation of the Heparanase Gene. Poster Session -- #3167 - Exposure of Human AML Cells to 5-Aza-2'-Deoxycytidine (decitabine) Alone or in Combination with Trichostatin A Induces p21CIP1 in the Absence of Dense Promoter Methylation. Poster Session -- #4571 - Impact of 5-azacytidine and 2'-deoxy-5-azacytidine (decitabine) on Histone Acetylation and Expression of the Non-Methylated p21WAF1/CIP1 Gene. Publication "The scope and depth of the scientific and clinical interest in Dacogen continues to strengthen our belief that this agent could become an important tool in the treatment of a variety of hematological conditions," said Craig Rosenfeld, M.D., Senior Vice President and Chief Scientific Officer of SuperGen. The primary mechanism of action for Dacogen in cancer is thought to be modification of aberrant DNA methylation, a major mechanism for regulating gene expression and reversing resistance to chemotherapy treatment. Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapeutic anticancer products. The Company's website can be reached at http://www.supergen.com/. This press release contains "forward-looking" statements within the meaning of section 21A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. Such forward-looking statements include statements related to our expectations regarding Dacogen as a single agent and in combination with other chemotherapeutic drugs in the treatment of various hematological conditions. The success of such product could differ materially from those discussed in the forward-looking statements as a result of known and unknown risk factors and uncertainties. Such factors include, but are not limited to: risks and uncertainties related to initiating, conducting and completing clinical trials, whether Dacogen will demonstrate any clinical benefit in any hematological conditions, and whether the company will submit Dacogen for regulatory approval for any indications, or if the drug will ever be approved or reach the market. References made to the discussion of the risk factors are detailed in the company's filing with the Securities and Exchange Commission including the report on Form 10-Q for the quarter ended September 30, 2003. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise. Contact: Tim Enns, Vice President, Investor Relations & Business Development, SuperGen, Inc., 800-353-1075, ext. 111 DATASOURCE: SuperGen, Inc. CONTACT: Tim Enns, Vice President, Investor Relations & Business Development, SuperGen, Inc., 800-353-1075, ext. 111 Web site: http://www.supergen.com/

Copyright